Table 2.
LP | PSP tau pathology | GCI pathology | Other types of pathology | |
---|---|---|---|---|
N | 162 | 45 | 28 | 58 |
Sex M, n (%) | 102 (63%) | 28 (62%) | 10 (36%)** | 36 (62%) |
Age at onset y, mean ± SD (range) < 50 / 50–75 / > 75 y, n (%) |
62 ± 11 (32–88) 26/117/19 (16/72/12%) |
66 ± 7 (51–84)** 0/40/5 (0/89/11%) |
59 ± 9 (45–81) 3/23/2 (11/82/7%) |
64 ± 12 (34–84) 7/43/8 (12/74/14%) |
Age at death y, mean ± SD (range) | 77 ± 8 (56–96) | 74 ± 8 (57–90) | 66 ± 9 (52–84)*** | 76 ± 11 (42–98) |
Disease duration y, mean ± SD (range) | 15 ± 7 (2–42) | 8 ± 4 (3–23)*** | 7 ± 3 (3–16)*** | 11 ± 9 (0.5–41)** |
Dementia, n (%) | 89 (55%) | 12 (27%)*** | 2 (7%)*** | 30 (52%) |
Duration of dementia y, mean ± SD (range) | 4 ± 3 (0–12) | 2 ± 2 (0–6)** | 1 ± 1 (0–1) | 3 ± 2 (0–10) |
Visual hallucinations, n/N (%) | 93/122 (76%) | 10/13 (77%) | 5/7 (71%) | 9/13 (69%) |
Rest tremor, n/N (%) | 112/134 (84%) | 11/30 (37%)*** | 16/24 (67%) | 29/37 (78%) |
Clear response to dopaminergic therapy, n/N (%) | 106/126 (84%) | 6/26 (23%)*** | 11/24 (46%)*** | 10/26 (39%)*** |
Positive family history of parkinsonism, n/N (%) | 31/80 (39%) | 7/28 (25%) | 3/17 (18%) | 8/29 (28%) |
APOE ε4 alleles, n/N (%) | ||||
0 | 67/101 (66%) | 23/39 (59%) | 12/23 (52%) | 33/43 (77%) |
1 | 31/101 (31%) | 15/39 (39%) | 9/23 (39%) | 9/43 (21%) |
2 | 3/101 (3%) | 1/39 (3%) | 2/23 (9%) | 1/43 (2%) |
Groups are compared using analysis of covariance for continuous variables and chi-square tests for categorical variables. When significant, the LP group was compared to the other pathology groups using post-hoc tests for continuous variable and chi-square tests for categorical variables.* p < 0.05; ** p < 0.01; *** p < 0.001